SCHEMBL1602172

SCHEMBL1602172

CCN(CC)c1cc(NN)nc(OCCN2CCOCC2)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 2/20 0.44
TYK2 P29597 1/20 0.44
BRSK1 Q8TDC3 1/20 0.44
IRAK4 Q9NWZ3 1/20 0.44
POLB P06746 1/20 0.41
TSHR P16473 1/20 0.39
ACHE P22303 2/20 0.38
BCHE P06276 1/20 0.38
MAOA P21397 1/20 0.38
MAOB P27338 1/20 0.38
HSP90AA1 P07900 1/20 0.38
HSP90AB1 P08238 1/20 0.38
CRHR1 P34998 1/20 0.38
NPC1 O15118 1/20 0.37
TLR7 Q9NYK1 1/20 0.37
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
MKNK1 Q9BUB5 1/20 0.37
GAA P10253 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14413070 0.91 CRHR1 (0.44) SYKTYK2BRSK1IRAK4POLB
SCHEMBL1603001 0.83 NPC1 (0.44) SYKPOLBTSHRACHEHSP90AA1
SCHEMBL2073676 0.80 SYK (0.64) SYKTYK2BRSK1IRAK4POLB
SCHEMBL14412522 0.80 CRHR1 (0.42) SYKPOLBCRHR1NPC1TLR7
SCHEMBL4151416 0.79 KMO (0.43) SYKPOLBTSHRNPC1KDM4E
SCHEMBL14530231 0.77 SYK (0.58) SYKTYK2BRSK1IRAK4POLB
SCHEMBL426631 0.77 PIKFYVE (0.58) SYKTYK2IRAK4POLBNPC1
SCHEMBL426630 0.77 PIKFYVE (0.58) SYKTYK2IRAK4POLBNPC1
SCHEMBL460359 0.76 AURKA (0.42) SYKACHEMAOAKDM4EALDH1A1
SCHEMBL427675 0.76 FES (0.42) SYKTYK2IRAK4POLBACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7919487-B2 Heteroaryl compounds SYNTA PHARMACEUTICALS CORPORATION (US) 2011-04-05 US disclosed
US-7919487-B2 Heteroaryl compounds SYNTA PHARMACEUTICALS CORPORATION (US) 2011-04-05 US disclosed
US-7919487-B2 Heteroaryl compounds SYNTA PHARMACEUTICALS CORPORATION (US) 2011-04-05 US disclosed
US-20060122156-A1 Heteroaryl compounds SYNTA PHARMACEUTICALS CORP. (US) 2006-06-08 US disclosed
WO-2006053109-A1 HETEROARYL COMPOUNDS SYNTA PHARMACEUTICALS CORP. (US) 2006-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060122156-A1 Heteroaryl compounds IL2, CCL11, IL4 SYK 739/4885TYK2 778/4885BRSK1 3062/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.